Menu Search
Equities

Medipharm Labs Corp

MLZ:DUS

Medipharm Labs Corp

Actions
  • Price (EUR)0.0426
  • Today's Change-0.003 / -6.99%
  • Shares traded--
  • 1 Year change-11.06%
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024 18:32 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in CADIncome statement in CADView more

Year on year Medipharm Labs Corp grew revenues 49.49% from 22.12m to 33.06m. Additionally the company has reduced the cost of goods sold, selling, general and administrative expenses and debt expenses (all as percentages of sales). These changes narrowed profitability losses from -29.98m to -13.08m.
Gross margin23.80%
Net profit margin-35.72%
Operating margin-37.12%
Return on assets-20.22%
Return on equity-25.30%
Return on investment-24.86%
More ▼

Cash flow in CADView more

In 2023, cash reserves at Medipharm Labs Corp fell by 6.16m. However, Cash Flow from Investing totalled 6.87m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 12.34m for operations while cash used for financing totalled 368.00k.
Cash flow per share-0.0291
Price/Cash flow per share--
Book value per share0.1158
Tangible book value per share0.1136
More ▼

Balance sheet in CADView more

Medipharm Labs Corp appears to have little financial risk as the company holds a substantial amount of cash on its books. In fact, 0.62% of the market capitalization can be attributed to its 17.98m and debt could be paid in full if management chose.
Current ratio3.11
Quick ratio2.33
Total debt/total equity0.059
Total debt/total capital0.0557
More ▼

Growth rates in CAD

SmartText is unavailable
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago		43.99
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.